After soaring in early pandemic days, Moderna has fallen into the doldrums. An explosive phase of growth may be ahead thanks ...

Moderna probably won't go down in history as a one-hit wonder, however. The biotech has a rich and diverse pipeline of candidates that could fuel a recovery in its stock performance.

Moderna's (NASDAQ: MRNA) sales are slowing down, and Moderna stock is going down -- a lot. The coronavirus vaccine maker's shares plunged 21.2% through 10:20 a.m. ET Monday after it updated ...

Moderna (NASDAQ: MRNA) was the top-performing stock in the S&P 500 not too long ago when the company joined the index in mid-2021. At its peak in 2021, the company's value soared to $187 billion ...

Moderna stock rallied 9% yesterday, after it launched phase 2/phase 3 clinical trials for a messenger RNA-based vaccine for skin cancer patients that it is developing with Merck. As per an earlier ...

Moderna's Q1 2022 financial performance was better than expected, but MRNA didn't raise full-year 2022 guidance. See if MRNA stock is a buy, sell, or hold.

And though share performance has cooled in recent times, the stock still has put a smile on the faces of long-term investors, climbing almost 400% over the past three years.

Moderna Inc. entered the new year on the heels of a worsening stock performance in 2024. The Cambridge drugmaker’s stock dropped even further after lowering its expected revenue range for 2025 ...

Moderna updated FY21 revenue guidance that came in below consensus estimates. The company also faces logistical issues. Find out if MRNA stock is a buy.